Renaissance Technologies LLC Has $5.44 Million Stock Holdings in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)

Renaissance Technologies LLC lowered its position in shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Free Report) by 9.1% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 686,500 shares of the company's stock after selling 69,100 shares during the quarter. Renaissance Technologies LLC owned approximately 0.22% of Amneal Pharmaceuticals worth $5,437,000 at the end of the most recent quarter.

Several other institutional investors have also recently added to or reduced their stakes in the company. Franklin Resources Inc. increased its holdings in shares of Amneal Pharmaceuticals by 4.9% during the third quarter. Franklin Resources Inc. now owns 89,887 shares of the company's stock worth $778,000 after buying an additional 4,178 shares in the last quarter. Arizona State Retirement System increased its holdings in Amneal Pharmaceuticals by 13.6% during the 4th quarter. Arizona State Retirement System now owns 40,401 shares of the company's stock valued at $320,000 after purchasing an additional 4,851 shares in the last quarter. Alliancebernstein L.P. raised its position in Amneal Pharmaceuticals by 2.5% in the 4th quarter. Alliancebernstein L.P. now owns 200,246 shares of the company's stock valued at $1,586,000 after purchasing an additional 4,927 shares during the last quarter. Globeflex Capital L P boosted its stake in Amneal Pharmaceuticals by 3.8% in the fourth quarter. Globeflex Capital L P now owns 144,439 shares of the company's stock worth $1,144,000 after purchasing an additional 5,245 shares in the last quarter. Finally, Empirical Financial Services LLC d.b.a. Empirical Wealth Management increased its stake in shares of Amneal Pharmaceuticals by 13.6% in the fourth quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management now owns 46,240 shares of the company's stock valued at $366,000 after buying an additional 5,523 shares in the last quarter. 31.82% of the stock is owned by institutional investors.

Insider Activity

In other Amneal Pharmaceuticals news, Director Gautam Patel sold 80,000 shares of the company's stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $8.90, for a total value of $712,000.00. Following the completion of the sale, the director now owns 1,808,886 shares of the company's stock, valued at approximately $16,099,085.40. This represents a 4.24 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, major shareholder Tushar Bhikhubhai Patel sold 5,000,000 shares of Amneal Pharmaceuticals stock in a transaction on Friday, March 14th. The stock was sold at an average price of $8.35, for a total transaction of $41,750,000.00. Following the transaction, the insider now directly owns 48,578,209 shares in the company, valued at approximately $405,628,045.15. This represents a 9.33 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 5,160,000 shares of company stock valued at $43,113,200 in the last 90 days. 17.45% of the stock is owned by company insiders.

Amneal Pharmaceuticals Stock Up 1.3 %

AMRX stock traded up $0.10 during midday trading on Friday, reaching $7.52. The stock had a trading volume of 440,610 shares, compared to its average volume of 1,400,913. The firm has a market cap of $2.33 billion, a price-to-earnings ratio of -11.05 and a beta of 1.06. Amneal Pharmaceuticals, Inc. has a twelve month low of $5.59 and a twelve month high of $9.48. The business has a fifty day simple moving average of $8.06 and a two-hundred day simple moving average of $8.21.

Amneal Pharmaceuticals (NASDAQ:AMRX - Get Free Report) last issued its quarterly earnings results on Friday, February 28th. The company reported $0.12 EPS for the quarter, missing the consensus estimate of $0.15 by ($0.03). Amneal Pharmaceuticals had a negative return on equity of 346.26% and a negative net margin of 6.88%. The business had revenue of $730.52 million for the quarter, compared to analyst estimates of $708.21 million. During the same quarter in the prior year, the firm earned $0.14 EPS. On average, equities analysts predict that Amneal Pharmaceuticals, Inc. will post 0.53 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

AMRX has been the topic of several research reports. Barclays upped their price target on shares of Amneal Pharmaceuticals from $10.00 to $11.00 and gave the stock an "overweight" rating in a research report on Monday, March 3rd. JPMorgan Chase & Co. upgraded shares of Amneal Pharmaceuticals from a "neutral" rating to an "overweight" rating and upped their target price for the stock from $9.00 to $12.00 in a research report on Monday, February 24th. Six research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Amneal Pharmaceuticals currently has a consensus rating of "Buy" and an average price target of $10.80.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.